Antineoplastic Agents

All Drugs and Chemicals

Lenvatinib

Tislelizumab

Temozolomide

Pamiparib

Antineoplastic Agents, Alkylating

Alkylating Agents

Protein Kinase Inhibitors

Enzyme Inhibitors

Antineoplastic Agents, Immunological

Poly(ADP-ribose) Polymerase Inhibitors

Sitravatinib

Ociperlimab

BAT1706

Fruquintinib

BGB-15025

Zanidatamab

BGB-A445

Surzebiclimab

LBL-007

Study Director

This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene investigational drugs in participants with advanced malignancies who participated in a prior BeiGene-sponsored clinical study (parent study).

For the purposes of this study, "study treatment" will refer to all investigational agents. A parent study is defined as the original BeiGene-sponsored clinical trial in which the participant was initially enrolled and received BeiGene investigational drugs (with or without other treatments).

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies

Safety as assessed by the number of participants with immune-mediated adverse events related to immunotherapy as assessed by the investigator, \> Grade 3 adverse events, Grade 2 adverse events that affect key organs (eg, heart, liver, brain, lung, kidney, eye), nonserious adverse events that lead to dose modification or drug discontinuation or withdrawal from the trial, and serious adverse events.

Overall survival defined as the time from start of treatment in the parent study (or randomization date for a randomized parent study) until the date of death from any cause.

BeiGene

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies	NCT04164199	Advanced Malign...	Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007	18 Years -	BeiGene
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies	NCT04164199	Advanced Malign...	Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007	18 Years -	BeiGene

Spots Global Cancer Trial Database for surzebiclimab